Outcomes in the second line treatment of metastatic colorectal cancer (mCRC): Findings from 6,462 patients (pts) in the ARCAD database.

Alexis D. Leal(Mayo Clinic in Arizona), Axel Grothey(Mayo Clinic), Marc Peeters(University of Antwerp), Levi Pederson(Mayo Clinic in Florida), Aimery de Gramont(Institut Hospitalier Franco Britannique), Fang‐Shu Ou(Mayo Clinic), Bruce J. Giantonio(Northwestern University), Eric Van Cutsem(Universitair Ziekenhuis Leuven), Alberto F. Sobrero(Ospedale Policlinico San Martino), Mace L. Rothenberg(Vanderbilt University), Dirk Arnold(Asklepios Klinik Altona), Henry C. Pitot(Mayo Clinic), Daniel J. Sargent(National Institute of Agricultural Botany)
Journal of Clinical Oncology
February 1, 2017
10.1200/jco.2017.35.4_suppl.757
Cited by 1

Related Papers

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
|The Lancet|2010|7.3k
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
|Journal of Clinical Oncology|1997|5.9k
Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
|Journal of Clinical Oncology|2000|3.8k